TriSalus Life Sciences (NASDAQ:TLSI) Coverage Initiated at Lake Street Capital

Stock analysts at Lake Street Capital assumed coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research report issued on Thursday, MarketBeat reports. The firm set a “buy” rating and a $10.00 price target on the stock. Lake Street Capital’s price target would suggest a potential upside of 76.99% from the stock’s previous close.

Several other brokerages also recently issued reports on TLSI. Northland Capmk raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Friday, October 25th. Roth Capital raised TriSalus Life Sciences to a “strong-buy” rating in a research report on Monday, November 11th. Northland Securities began coverage on TriSalus Life Sciences in a research report on Friday, October 25th. They set an “outperform” rating and a $12.50 target price on the stock. Roth Mkm reissued a “buy” rating and set a $11.00 target price on shares of TriSalus Life Sciences in a research report on Friday, January 24th. Finally, Canaccord Genuity Group decreased their target price on TriSalus Life Sciences from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Eight research analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $11.56.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ:TLSI opened at $5.65 on Thursday. The company has a market cap of $172.27 million, a P/E ratio of -2.27 and a beta of 0.51. The stock’s 50-day moving average is $4.82 and its 200-day moving average is $4.74. TriSalus Life Sciences has a 52-week low of $3.50 and a 52-week high of $10.42.

Insider Buying and Selling at TriSalus Life Sciences

In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius bought 62,972 shares of the company’s stock in a transaction on Tuesday, December 17th. The stock was bought at an average price of $3.97 per share, for a total transaction of $249,998.84. Following the transaction, the insider now owns 6,230,748 shares of the company’s stock, valued at approximately $24,736,069.56. The trade was a 1.02 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Mary T. Szela purchased 4,826 shares of the firm’s stock in a transaction dated Monday, January 27th. The stock was purchased at an average cost of $5.42 per share, with a total value of $26,156.92. Following the acquisition, the chief executive officer now directly owns 429,503 shares in the company, valued at $2,327,906.26. This trade represents a 1.14 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders acquired 124,868 shares of company stock worth $575,843. Insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Walleye Capital LLC acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $66,000. Renaissance Technologies LLC acquired a new position in shares of TriSalus Life Sciences in the 4th quarter valued at $67,000. Virtu Financial LLC acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $92,000. Vestcor Inc acquired a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $108,000. Finally, Northern Trust Corp grew its holdings in shares of TriSalus Life Sciences by 22.7% in the 4th quarter. Northern Trust Corp now owns 32,112 shares of the company’s stock valued at $161,000 after buying an additional 5,936 shares during the period. Institutional investors and hedge funds own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.